Business context and reporting period
Entity discrepancy: The request identifies Gyre Therapeutics, Inc., but the supplied Form 10-Q is for Targacept, Inc. It covers the quarter ended March 31, 2012 and was filed May 9, 2012. Targacept was a clinical-stage biopharmaceutical company developing neuronal nicotinic receptor therapeutics; it had no approved products or product-sales revenue.
Financial performance and position
| Metric | Q1 2012 | Q1 2011 / comparison |
|---|---|---|
| Operating revenue | $22.9 million | $39.0 million; down $16.1 million (41%) |
| Operating expenses | $20.9 million | $26.7 million |
| Operating income and margin | $2.0 million; 8.7% | $12.3 million; 31.5% |
| Net income and diluted EPS | $2.3 million; $0.07 | $12.6 million; $0.41 |
| Operating cash flow | $(24.9) million | $(22.0) million |
Revenue consisted primarily of collaboration license fees and milestones ($22.6 million); grant revenue was $0.25 million. Lower revenue chiefly reflected the absence of $18.4 million in GSK deferred-revenue recognition and $2.4 million in TC-5619 revenue recognized in Q1 2011. These declines were partly offset by increased recognition of the TC-5214 upfront payment. Q1 2011 income also included accelerated GSK deferred revenue after termination, making the year-over-year comparison unusually high.
Cash and cash equivalents were $88.7 million at March 31, down from $107.3 million at year-end. Cash, cash equivalents and marketable securities totaled $223.7 million, versus $249.3 million at December 31. Total assets were $231.1 million; current assets were $179.3 million and current liabilities $48.2 million. Debt totaled approximately $2.7 million, with no remaining borrowing capacity. Accumulated deficit was $224.7 million. No income tax expense was recorded.
Material changes, outlook and risks
- Research and development expense fell 24% to $17.8 million, largely as TC-5214 Phase 3 activity wound down; general and administrative expense was $3.1 million, down slightly.
- Neither of the final two Phase 3 TC-5214 adjunct-treatment trials met its primary endpoint. The company said no regulatory filing would be pursued; a separate Phase 2b switch-monotherapy trial was discontinued. AstraZeneca gave notice in April 2012 to terminate the TC-5214 agreement, effective in late May. Targacept remained responsible for 20% of certain remaining program costs.
- After quarter-end, Targacept announced a workforce reduction of 65 employees, approximately 46% of its workforce, with completion expected by the end of Q2 2012. It recorded $2.386 million of related severance and other charges in April.
- Management expected 2012 revenue to decrease from 2011, partly because TC-5214 upfront-payment recognition would end in mid-2012. It expected R&D expense to decline year over year but remain significant, including for two Phase 2 TC-5619 trials and the AZD3480 Phase 2b Alzheimer’s trial.
- Management estimated existing capital resources would fund operations through at least the end of 2015, excluding potential AstraZeneca milestones. This is an estimate subject to development spending, collaboration decisions, and access to financing. Management also cited dependence on AstraZeneca, uncertain clinical outcomes and milestone timing, and the risk that additional capital may be needed sooner than expected.
- TC-5619 was in two Phase 2 trials; AZD3480 was in a Phase 2b Alzheimer’s trial. AstraZeneca controlled substantial development decisions for AZD3480 and AZD1446. The filing said no AZD3480 or AZD1446 contingent milestone was expected to be achievable during 2012 based on projected timelines.
Important facts for investors to verify
- Confirm the intended issuer: the supplied filing is Targacept’s, not Gyre Therapeutics’.
- Review the TC-5214 termination’s effective date, remaining costs and effect on future collaboration revenue.
- Assess cash burn and the assumptions behind management’s projected runway through 2015, particularly after the workforce reduction.
- Track TC-5619 and AZD3480 clinical progress and AstraZeneca’s plans for AZD3480 and AZD1446; potential milestones are uncertain and not included in the runway estimate.
- Consider the effect of deferred-revenue recognition ending and the unusual GSK-related revenue in the prior-year comparison.